Dominic Schmidt
General Partner at Advent Life Sciences
Greater London, England
Overview
Work Experience
Non Executive Director
2024 - Current
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
Raised $80,000,000.00 from Mission BioCapital, Sanofi Ventures, Remiges Ventures, Chiesi Ventures, RiverVest, Novo Holdings, Abingworth, Sanderling Ventures, Asahi Kasei and Asahi Kasei.
General Partner
2022
Investing and building companies in biotech. Venture/Growth.
Board Observer
2024
Non Executive Director
2024
Non Executive Director
2022
Non Executive Director
2022
Non Executive Director
2020 - 2022
Non Executive Director
2020 - 2022
Non Executive Director
2019 - 2022
Partner
2016 - 2022
Syncona is a leading FTSE 250 company focused on investing in and building global leaders in life science.
Partner
2014 - 2016
Syncona operates as an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to significantly impact the healthcare market of the future. Syncona is an investor that can take the long view when necessary, able to concentrate investment into opportunities as technology is validated.